Last reviewed · How we verify
LiquiTears — Competitive Intelligence Brief
marketed
Artificial tear / Lubricating ophthalmic solution
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
LiquiTears (LiquiTears) — Chakshu Research, Inc.. LiquiTears is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LiquiTears TARGET | LiquiTears | Chakshu Research, Inc. | marketed | Artificial tear / Lubricating ophthalmic solution | ||
| Tears Naturale II Ophthalmic Solution | Tears Naturale II Ophthalmic Solution | ORA, Inc. | marketed | Artificial tear / Lubricating ophthalmic solution |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Artificial tear / Lubricating ophthalmic solution class)
- Chakshu Research, Inc. · 1 drug in this class
- ORA, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LiquiTears CI watch — RSS
- LiquiTears CI watch — Atom
- LiquiTears CI watch — JSON
- LiquiTears alone — RSS
- Whole Artificial tear / Lubricating ophthalmic solution class — RSS
Cite this brief
Drug Landscape (2026). LiquiTears — Competitive Intelligence Brief. https://druglandscape.com/ci/liquitears. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab